Evidence map›Paper›PMID 40205626›Full record

ArticleJournal of applied clinical medical physics2025

Design and validation of a novel dosimetry phantom for motion management audits.

Alex Burton, Sabeena Beveridge, Nicholas Hardcastle, Silvio Malfitana, Janaka Madamperuma, Rick Franich

Abstract readValidation Study
In one paragraph

Article in Journal of applied clinical medical physics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alex BurtonAustralian Clinical Dosimetry Service (ACDS), Australian Radiation Protection and Nuclear Safety Agency (ARPANSA), Yallambie, Victoria, Australia.
Sabeena BeveridgeAustralian Clinical Dosimetry Service (ACDS), Australian Radiation Protection and Nuclear Safety Agency (ARPANSA), Yallambie, Victoria, Australia.
Nicholas HardcastleDepartment of Physical Sciences, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Silvio MalfitanaAustralian Clinical Dosimetry Service (ACDS), Australian Radiation Protection and Nuclear Safety Agency (ARPANSA), Yallambie, Victoria, Australia.
Janaka MadamperumaAustralian Clinical Dosimetry Service (ACDS), Australian Radiation Protection and Nuclear Safety Agency (ARPANSA), Yallambie, Victoria, Australia.
Rick FranichDepartment of Physical Sciences, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe present a novel phantom design for conducting end-to-end dosimetry audits for respiratory motion management of two anatomical treatment sites. The design enables radiochromic film measurements of the dose administered to the target throughout the respiratory cycle (motion-included) and the dose delivered to the time-averaged motion of the phantom (motion-excluded) to be conducted simultaneously. PURPOSE: To demonstrate the phantom's utility in a dosimetry audit and capacity to detect errors by quantifying spatial and dosimetric reproducibility.

methodsSpatial and dosimetric reproducibility was quantified by repeat exposures using a simple lateral beam. Five exposures per measurement configuration were used. In each series of five measurements, the median film was used as the series reference to quantify the reproducibility of the remaining "test films." Spatial reproducibility was quantified by comparing the position of isodose lines in two axes on the test films back to the series reference. Dosimetric reproducibility was quantified using gamma comparison between each test film and the series reference. Proof-of-concept of the motion-excluded measurement capability was also established by comparing all films to treatment planning system (TPS) calculated dose distributions.

resultsSpatial reproducibility was better than 1 mm on all assessed metrics across all measurements. Film-to-film local gamma passing rates at 3%/0.6 mm were above 90% for all measurements. Film-to-TPS global gamma passing rates at 3%/1 mm were >95% in the motion-excluded measurement series', but <80% in the motion-included series, highlighting the utility of the motion-excluded measurements.

conclusionsMeasurements were highly reproducible and of sufficient accuracy/reproducibility to facilitate multiple avenues of analysis in a prospective dosimetry audit. Motion-excluded measurements were directly comparable to the TPS dose distribution. Motion-included measurements may yield more clinically-relevant information about the actual dose administered to the target. This promises greater sensitivity to motion management-related errors, detectable in the setting of a dosimetry audit for motion management.

Indexed as

Film DosimetryPhantoms, ImagingRadiometryRadiotherapy Planning, Computer-AssistedHumansMovementRadiotherapy DosageRadiotherapy, Intensity-ModulatedReproducibility of Resultsdosimetry auditmotion managementradiochromic film

Identifiers

PMID40205626
PMCPMC12148796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.